CIK 0001604821 · Large accelerated filer
Natera, Inc.
Sign in to watch- Ticker
- NTRA
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 010894487
- Phone
- 650-249-9090
- Business address
- 13011 MCCALLEN PASS, BUILDING A SUITE 100, AUSTIN, TX, 78753
- Former names
- Natera, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $104,832,418
- in 28 filings, $104.8M under 10b5-1 plans
Net −$104,832,418. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Rabinowitz Matthew −$72.3M EXECUTIVE CHAIRMAN sold 9% of stake
- Sheena Jonathan −$13.8M Director sold 83% of stake
- Moshkevich Solomon −$9.5M PRESIDENT, CLINICALDIAGNOSTICS sold 21% of stake
- Chapman Steven Leonard −$5.0M CEO AND PRESIDENT sold 12% of stake
- Brophy Michael Burkes −$2.5M CHIEF FINANCIAL OFFICER sold 11% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-15 | Sheena Jonathan Director | Sale 10b5-1 | −6,000 | $350.07 | $2.1M | 224,464 |
| 2026-09-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −1,481 | $339.24 | $502K | 2,173,913 |
| 2026-09-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −2,549 | $340.25 | $867K | 2,171,364 |
| 2026-09-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −1,813 | $341.41 | $619K | 2,169,551 |
| 2026-09-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −1,956 | $342.18 | $669K | 2,167,595 |
| 2026-09-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −2,240 | $343.56 | $770K | 2,165,355 |
| 2026-09-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −5,839 | $344.49 | $2.0M | 2,159,516 |
| 2026-09-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −2,700 | $345.38 | $933K | 2,156,816 |
| 2026-09-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −1,122 | $346.68 | $389K | 2,155,694 |
| 2026-09-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −2,700 | $347.81 | $939K | 2,152,994 |
| 2026-09-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −8,094 | $348.65 | $2.8M | 2,144,900 |
| 2026-09-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −4,206 | $349.51 | $1.5M | 2,140,694 |
| 2026-09-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −14,500 | $350.81 | $5.1M | 2,126,194 |
| 2026-09-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −800 | $351.25 | $281K | 2,125,394 |
| 2026-09-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −2,000 | $350.01 | $700K | 0 |
| 2026-09-14 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −1,537 | $328.09 | $504K | 2,223,857 |
| 2026-09-14 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −6,015 | $329.12 | $2.0M | 2,217,842 |
| 2026-09-14 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −6,206 | $330.05 | $2.0M | 2,211,636 |
| 2026-09-14 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −3,494 | $330.98 | $1.2M | 2,208,142 |
| 2026-09-14 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −1,000 | $332.02 | $332K | 2,207,142 |
Page 8 of 39 · 767 trades